2025-05-28 11:04
publication
2025-05-28 11:04
The diagnostic group in 2025 expect a single -digit increase in test volumes and about 10 percent. an increase in their average price and maintenance of the level of profitability – the company's representatives informed. The Management Board estimates that the new “My Health” program will have a less positive impact than “Prevention 40 Plus”.
“As for volumes, we will observe increases at the level of high single digit RDR, which will be caused by our organic growth and market trends. When it comes to prices, the average price will increase and RDR will be about 10 percent – this is due to the inclusion of imaging diagnostics in consolidation, but also in the increases that we introduce in specialist segments. During the video conferencing, Vice President Paweł Chyłła asked about the perspectives regarding the volumes of research and prices at 2025.
The diagnostic group in the first quarter of 2025 recorded an increase in the volume of research by 8.3 percent. yard to 45.2 million. The average test price increased by 14.1 percent. rdr.
“We grow strongly over 8 % (…) The program +40 plus +prevention was significantly influenced, but let's not forget that it was 4 percent of our results in the first quarter, so we are also talking about the organic growth of important customers” – said the vice president.
“Prices are also rising. It is the impact of the product and client mix, while prices actually rise. These are not increases introduced in the first quarter, our price increases process is continuous” – he added.
The Group's revenues from operating activities amounted to PLN 594.9 million (+22.5 percent yaws) in the first quarter of 2025, including revenues from contracts with clients PLN 591.6 million (+23.1 percent of the yard).
“Revenues increased (…), which was related to, among others, inflationary pressure. In addition, a mix of research goes towards more expensive research in connection with our specialization and specialist studies, in particular it will grow, because the number of imaging diagnostics tests in the mix of our research increases” – added President Jakub Swadźba.
In April, the program “Prevention 40 Plus” was completed and was replaced by a new initiative – the “My Health” program, based on different assumptions.
“From the point of view of financial results, this is not significant, but we anticipate that the program + my health + will have a less positive impact on us than the previous program. Reaching people will be more difficult. We assess this project generally negatively, although the premises for its introduction were good (…). It seems that the mechanisms introduced in it will not be checked and the program will have to be corrected and will not be a common program” – assessed the president.
“On the other hand, it seems that it will be a situation for us that people will just want to study and increase our sales of B2C, although in 2025 a lot of people have undergone preventive examinations (…) and I think that the B2C market will increase more in 2026 than 2025.” he added.
The company is expecting a positive impact in connection with a change in the cervical cancer prevention program.
“A change has been introduced in the cervical cancer prevention program and we will take part in competitions for participation in the program (…). Due to this project, we expect increased revenues” – added Swadźba.
In 2025, the Management Board expects to maintain the level of profitability.
“We are rather talking about the stable profitability of EBITDA, as at the end of 2024 (…) I would expect a similar level of profitability this year,” he said sly.
In 2024, the Recurring EBITDA margin increased by 2.0 pp to 26.1 percent.
The presentation stated that at the end of the first quarter of 2025, the group had available cash in the amount of approx. PLN 330 million.
According to the management board, in the first quarter, acquisition expenses were suspended in connection with the IPO process, but since Q2, the acquisition activities are continued. (PAP Biznes)
doa/ ry/
